Skip to main content

Table 3 An internal dose-response analysis.

From: Digitoxin medication and cancer; case control and internal dose-response studies

ICD-10 Site Digitoxin concentration ng/ml
   <16 16–22 >22
C50 Breast 1.00 (reference) 1.04(0.59, 1.84) 0.90(0.48, 1.67)
C61 Prostate 1.00 (reference) 0.79(0.51, 1.22) 0.89(0.56, 1.40)
C18–C21 Colo-rectal 1.00 (reference) 0.97(0.66, 1.42) 0.92(0.61, 1.40)
C32–C34 Lung 1.00 (reference) 1.25(0.71,2.22) 1.06(0.57,2.00)
C64, C65 Kidney, urinary 1.00 (reference) 0.30(0.15,0.57) 0.45 (0.24, 0.83)
C67, C68 organs    
C43,C44 Melanoma, other 1.00 (reference) 1.16(0.60,2.25) 1.29(0.65,2.57)
  skin    
C81–C85 Leukemia and 1.00 (reference) 0.67(0.38, 1.18) 0.57(0.30, 1.08)
C88–C92 Lymphoma    
C00-C97 All sites 1.00 (reference) 0.84(0.71,0.99) 0.86(0.72, 1.02)
  1. An internal dose-response analysis. Age-adjusted relative risks (95% confidence limits) of specific types of cancer by concentration levels (tertiles) of digitoxin. A Cox regression analysis was used.